These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 21830317)

  • 21.
    Harun SN; Holford NHG; Grimwood K; Wainwright CE; Hennig S;
    Thorax; 2019 Aug; 74(8):740-748. PubMed ID: 31203197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failed Eradication Therapy of New-Onset Pseudomonas aeruginosa Infections in Children With Cystic Fibrosis Is Associated With Bacterial Resistance to Neutrophil Functions.
    Kwong K; Benedetti A; Yau Y; Waters V; Nguyen D
    J Infect Dis; 2022 Jun; 225(11):1886-1895. PubMed ID: 33606875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real world evaluation of the long-term efficacy of strategies to prevent chronic Pseudomonas aeruginosa pulmonary infection in children with cystic fibrosis.
    Mostofian F; Alkadri J; Tang K; Thampi N; Radhakrishnan D
    Int J Infect Dis; 2019 Aug; 85():92-97. PubMed ID: 31132474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
    Zemanick ET; Wagner BD; Harris JK; Wagener JS; Accurso FJ; Sagel SD
    Pediatr Pulmonol; 2010 Jun; 45(6):569-77. PubMed ID: 20503282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Wood DM; Smyth AR
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004197. PubMed ID: 16437476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
    Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.
    Troxler RB; Hoover WC; Britton LJ; Gerwin AM; Rowe SM
    Pediatr Pulmonol; 2012 Nov; 47(11):1113-22. PubMed ID: 22496040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
    Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
    Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
    [No Abstract]   [Full Text] [Related]  

  • 30. Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis.
    Cohen-Cymberknoh M; Gilead N; Gartner S; Rovira S; Blau H; Mussaffi H; Rivlin J; Gur M; Shteinberg M; Bentur L; Livnat G; Aviram M; Picard E; Tenenbaum A; Armoni S; Breuer O; Shoseyov D; Kerem E
    J Cyst Fibros; 2016 Nov; 15(6):776-782. PubMed ID: 27143583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of different eradication treatment protocols for new-onset Pseudomonas aeruginosa in children with cystic fibrosis.
    Sunman B; Emiralioglu N; Hazirolan G; Şener B; Ozsezen B; Tural DA; Buyuksahin HN; Guzelkas I; Yalcin E; Dogru D; Özçelik U; Kiper N
    Pediatr Pulmonol; 2022 Jun; 57(6):1456-1465. PubMed ID: 35229497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eradication of Pseudomonas aeruginosa in an adult patient with cystic fibrosis.
    Hayes D; Feola DJ; Murphy BS; Kuhn RJ; Davis GA
    Am J Health Syst Pharm; 2011 Feb; 68(4):319-22. PubMed ID: 21289326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis.
    Zemanick ET; Emerson J; Thompson V; McNamara S; Morgan W; Gibson RL; Rosenfeld M;
    Pediatr Pulmonol; 2015 Jan; 50(1):42-8. PubMed ID: 24644274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Smith S; Ratjen F; Remmington T; Waters V
    Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.
    Anstead M; Heltshe SL; Khan U; Barbieri JT; Langkamp M; Döring G; Dharia S; Gibson RL; Treggiari MM; Lymp J; Rosenfeld M; Ramsey B
    J Cyst Fibros; 2013 Mar; 12(2):147-53. PubMed ID: 22944725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.
    Vidya P; Smith L; Beaudoin T; Yau YC; Clark S; Coburn B; Guttman DS; Hwang DM; Waters V
    Eur J Clin Microbiol Infect Dis; 2016 Jan; 35(1):67-74. PubMed ID: 26492874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.